Nakopoulou Lydia, Giannopoulou Ioanna, Trafalis Dimitrios, Gakiopoulou Hariklia, Keramopoulos Antonios, Davaris Panayiotis
Department of Pathology, Medical School, The National and Kapodistrian University of Athens, Greece.
Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):20-8. doi: 10.1097/00129039-200203000-00004.
Breast cancer is a genetically complex disease and is frequently associated with nonrandom chromosomal alterations. The occurrence of aberrations involving chromosomes 1 and 17 in malignant tissues of breast cancer patients has not been studied systematically. The numeric aberrations of chromosomes 1 and 17 were detected by nonisotopic in situ hybridization on paraffin-embedded tissue sections from 44 invasive breast carcinomas (42 cases available for chromosome 17) and were correlated with clinicopathologic parameters, patients' survival, p53, and c-erbB-2 proteins. Chromosome 17 and 1 aneuploidy were observed in the majority of breast carcinomas with equal percentages of polysomy and monosomy for chromosome 17 and predominance of polysomy for chromosome 1. Monosomy of chromosome 17 was significantly associated with positive lymph nodes and negative estrogen receptor (ER) immunohistochemical expression. Patients with chromosome 17 monosomy were at greater risk of death. Ductal carcinoma displayed a greater percentage of chromosome 1 polysomy than lobular ones. A statistically significant association was demonstrated between chromosome 1 polysomy and higher nuclear grade. Patients with chromosome 1 aneuploidy were at greater risk of death, and especially those with ER negativity. Aneuploid patients with c-erbB-2(-)/PR(-) phenotype demonstrated lower survival rates. These data suggest a possible susceptibility of chromosome 17 to losses and gains and chromosome 1 to gains. Chromosome 17 monosomy and chromosome 1 aneuploidy may be useful prognostic markers in breast cancer patients.
乳腺癌是一种基因复杂的疾病,常与非随机染色体改变相关。乳腺癌患者恶性组织中涉及1号和17号染色体的畸变发生情况尚未得到系统研究。通过非同位素原位杂交技术,对44例浸润性乳腺癌石蜡包埋组织切片(42例可用于检测17号染色体)进行1号和17号染色体的数目畸变检测,并将其与临床病理参数、患者生存率、p53和c-erbB-2蛋白进行相关性分析。在大多数乳腺癌中观察到17号和1号染色体非整倍体,17号染色体多体和单体的比例相等,1号染色体以多体为主。17号染色体单体与阳性淋巴结和雌激素受体(ER)免疫组化阴性表达显著相关。17号染色体单体的患者死亡风险更高。导管癌的1号染色体多体百分比高于小叶癌。1号染色体多体与较高的核分级之间存在统计学显著关联。1号染色体非整倍体的患者死亡风险更高,尤其是ER阴性的患者。c-erbB-2(-)/PR(-)表型的非整倍体患者生存率较低。这些数据表明17号染色体可能易发生缺失和增加,1号染色体易发生增加。17号染色体单体和1号染色体非整倍体可能是乳腺癌患者有用的预后标志物。